Copper Cu 64 dotatate

Copper Cu 64 dotatate is a radiopharmaceutical used in Positron Emission Tomography (PET) imaging for the detection of somatostatin receptor positive neuroendocrine tumors. It is a copper-64 radiolabeled somatostatin analog.

History

Copper Cu 64 dotatate was approved by the United States Food and Drug Administration (FDA) in 2021, making it the first drug of its kind to be approved for use in the United States.

Mechanism of Action

Copper Cu 64 dotatate works by binding to somatostatin receptors, which are overexpressed in certain types of neuroendocrine tumors. The copper-64 isotope emits positrons that can be detected by a PET scanner, allowing for the visualization of the tumor.

Uses

Copper Cu 64 dotatate is used in PET imaging to detect somatostatin receptor positive neuroendocrine tumors. It is not used for treatment, but rather for diagnostic purposes.

Side Effects

As with all radiopharmaceuticals, Copper Cu 64 dotatate carries a risk of radiation exposure. Other potential side effects include nausea, vomiting, and allergic reactions.

See Also

• Radiopharmaceutical
• Positron Emission Tomography
• Somatostatin receptor
• Neuroendocrine tumor

‎ ‎

---

Translate: - East Asian 中文, 日本, 한국어, South Asian हिन्दी, தமிழ், తెలుగు, Urdu, ಕನ್ನಡ, Southeast Asian Indonesian, Vietnamese, Thai, မြန်မာဘာသာ, বাংলা
European español, Deutsch, français, Greek, português do Brasil, polski, română, русский, Nederlands, norsk, svenska, suomi, Italian
Middle Eastern & African عربى, Turkish, Persian, Hebrew, Afrikaans, isiZulu, Kiswahili,
Other Bulgarian, Hungarian, Czech, Swedish, മലയാളം, मराठी, ਪੰਜਾਬੀ, ગુજરાતી, Portuguese, Ukrainian